Abciximab
ApprovedCompleted 1 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Myocardial Infarction
Conditions
Myocardial Infarction, Ischemia
Trial Timeline
Feb 1, 2007 → May 1, 2013
NCT ID
NCT00440895About Abciximab
Abciximab is a approved stage product being developed by Eli Lilly for Myocardial Infarction. The current trial status is completed. This product is registered under clinical trial identifier NCT00440895. Target conditions include Myocardial Infarction, Ischemia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00178451 | Phase 1/2 | Withdrawn |
| NCT00440895 | Approved | Completed |
| NCT00440778 | Approved | Completed |
| NCT00420030 | Approved | Completed |
| NCT00354406 | Approved | Completed |
| NCT00167765 | Phase 3 | Terminated |
| NCT00126139 | Phase 3 | Terminated |
| NCT00073372 | Phase 3 | Terminated |
| NCT00169819 | Approved | Completed |
Competing Products
20 competing products in Myocardial Infarction